Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of recombinant factor VIIa (LR769) for bleeding episodes in congenital hemophilia A or B with inhibitors
2013-004779-11Phase 3Completed
- Sponsor
- rEVO Biologics
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Coagulation factor VIIa recombinant human in hemophilia A and hemophilia B (HB) (2 arms), sponsored by rEVO Biologics. Primary endpoint: Successful treatment of a bleeding episode. Started May 2014; status: completed.
02
Drugs
Coagulation factor VIIa recombinant human
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2013-004779-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004779-11.